Perseus Proteomics Inc. (TYO:4882)

Revenue by Product

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Antibody and Reagent Sales	96.02M
Antibody and Reagent Sales Growth	20.53%
Antibody Research Support	24.35M
Antibody Research Support Growth	17.44%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United States	69.08M
United States Growth	24.60%
Japan	51.29M
Japan Growth	14.08%